Freenome said the FDA approved its SimpleScreen blood-based colorectal cancer screening test, extending access for average-risk adults who are currently underserved by existing screening coverage. The approval positions the test for potential Medicare coverage and places Freenome’s personalized cancer detection approach into a commercialization-ready phase, with Abbott holding exclusive U.S. commercialization rights. Under the deal, Abbott is expected to pay Freenome a $100 million milestone in exchange for exclusivity, and Freenome expects screening uptake to broaden as blood testing reduces barriers tied to stool-based screening participation.